Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.

Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.

Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.

Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.

Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.

Abstract: The present invention relates to the fields of hematopoietic stem cell transplantation and molecular biology. More specifically, methods for improving engraftment efficiency in stem cell transplants by improving stem cell homing to bone marrow are provided.

Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed.

Abstract: Certain nitrogen-containing compounds that bind the chemokine receptor CXCR4 are able to mobilize progenitor and/or stem cells into the peripheral blood to permit harvesting them for stem cell transplantation.

Abstract: The present invention relates to the fields of hematopoietic stem cell transplantation and molecular biology. More specifically, methods for improving engraftment efficiency in stem cell transplants by improving stem cell homing to bone marrow are provided.

Abstract: The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.

Abstract: The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.

Abstract: The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of the invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for autologous (self) reconstitution.

Abstract: Full length cDNAs, L2G25B and 4-1BB, were isolated and sequenced. The cDNA L2G25B encodes for the lymphokine, macrophage inflammatory protein-1&agr; or MIP-1&agr;. The studies disclosed herein suggest that MIP-1&agr; and MIP-&bgr; can, through rapid action, modulate early myeloid progenitor cell proliferation. Recombinant proteins have been produced for the cytokine, L2G25BP (Macrophage Inflammatory Protein-1&agr;, MIP-1&agr;). By employing the recombinant protein (rMIP-1&agr;), receptors for MIP-1&agr; were identified on Con A-stimulated and unstimulated CTLL-R8, a T-cell line, and LPS-stimulated RAW 264.7, a macrophage-cell line. Purified recombinant murine macrophage inflammatory protein-1 alpha (rmuMIP-&agr;), was assessed for effects on proliferation of granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells. The results suggest that rmuMIP-1&agr; has myelosuppressive activity in vivo.

Abstract: The inventors have cloned and expressed the chemokine-like genes from MCV type 1 and the closely related MCV type 2 in order to determine a potential role for these proteins in the viral life cycle. These are the first viral chemokines that have been shown to antagonize the chemotactic activity of human chemokines and the first viral chemokines that have been shown to have inhibitory activity on human hematopoietic progenitor cells. Methods and compositions for exploiting these proteins are disclosed herein.

Abstract: Described are preferred processes and compositions for suppressing myeloid cells in mammals. Preferred processes and compositions involve the use of chemokines in synergistic combinations or while they are substantially completely in monomeric form (i.e. substantially free from their polymerized or aggregated forms).

Abstract: Described are preferred processes for suppressing proliferation of or for myeloprotecting myeloid cells in mammals. The processes involve the use of chemokines of the group Macrophage Inflammatory Protein-2.alpha. (MIP-2.alpha.), Platelet Factor 4 (PF4), Interleukin-8 (IL-8) and Macrophage Chemotactic and Activating Factor (MCAF), or involve the use of these chemokines or Macrophage Inflammatory Protein-1.alpha. (MIP-1.alpha.) in synergistic combinations or while they are substantially completely in monomeric form (i.e. substantially free from their polymerized or aggregated forms).

Abstract: The present invention discloses the correct processing of IP-10, a myelosuppressive protein produced by certain cells such as keratinocytes, monocytes and human endothelial cells upon stimulation by .gamma.-interferon. Also disclosed is a method of treating human cancer patients by applying IP-10 in a pharmaceutical composition in conjunction with certain antineoplastic agents.

Abstract: The invention comprises a factor having the following characteristics:a) It inhibits granulocyte-macrophage colony and cluster formation;b) It has a molecular weight of about 8 kDa as determined by SDS-PAGE;c) It has a weak anionic charge at pH 7.4 as shown by anion exchange chromatography;d) It has a flattened isoelectric titration curve as shown by anion exchange chromatography; andd) It is a protein.The invention also comprises methods of making and using the factor and compositions comprising the factor.

Abstract: The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. Hematopoietic reconstitution with the cells of the invention can be valuable in the treatment or prevention of various diseases and disorders such as anemias, malignancies, autoimmune disorders, and various immune dysfunctions and deficiencies. In another embodiment, fetal or neonatal hematopoietic stem and progenitor cells which contain a heterologous gene sequence can be used for hematopoietic reconstitution in gene therapy. In a preferred embodiment of he invention, neonatal or fetal blood cells that have been cryopreserved and thawed can be used for utologous (self) reconstitution.

Abstract: The invention comprises a factor having the following characteristics:a) It inhibits granulocyte-macrophage colony and cluster formation;b) It has a molecular weight of about 8 kDa as determined by SDS-PAGE;c) It has a weak anionic charge at pH 7.4 as shown by anion exchange chromatography;d) It has a flattened isoelectric titration curve as shown by anion exchange chromatography; ande) It is a protein.The invention also comprises methods of making and using the factor and compositions comprising the factor.